Sex differences in serious adverse drug reactions in patients receiving immunotherapy, targeted therapy, or chemotherapy: a disproportionality analysis of the VigiBase®. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Clinical Pharmacology Année : 2022

Sex differences in serious adverse drug reactions in patients receiving immunotherapy, targeted therapy, or chemotherapy: a disproportionality analysis of the VigiBase®.

Fichier non déposé

Dates et versions

hal-04606962 , version 1 (10-06-2024)

Identifiants

Citer

Guillaume Wabont, Sandrine Bergeron, Sophie Gautier, Romain Barus. Sex differences in serious adverse drug reactions in patients receiving immunotherapy, targeted therapy, or chemotherapy: a disproportionality analysis of the VigiBase®.. European Journal of Clinical Pharmacology, 2022, European Journal of Clinical Pharmacology, 78, pp.1355-1356. ⟨10.1007/s00228-022-03332-z⟩. ⟨hal-04606962⟩

Collections

UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More